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• 8,841 eligible patients who initiated an ADF. 
• 2,332 (26%) were classified as traditional new-users
• 6,509 (74%) were prevalent new-users with prior exposure to immediate-release (IR) or extended-
release/long-acting (ER/LA) opioids
• Most traditional new-users started with an ADF and an immediate-release (IR) opioid concurrently (85%). 
• Among prevalent new-users, common ADF initiation patterns were: 
• Adding an ADF to an IR opioid regimen (43%), 
• A direct switch from IR opioids to an ADF (15%), 
• Delayed switch from IR opioids to an ADF (14%)
• Prevalent new-users continued to receive opioid prescriptions after ADF initiation far more than traditional 
new-users (Figure 1).
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Study Sample
• Patients aged 18-64 
• Initiating an ADF opioid
• 6 months of continuous enrollment prior to 
first ADF claim
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Figure 1. Patterns of opioid use by (A) Traditional new-user, (B) Prevalent new-user status at ADF initiation
A. B.
• Currently marketed abuse-deterrent formulation (ADF) opioids are routinely used in patients with prior 
prescription opioid exposure. 
• Traditional new-user design excludes patients with prior exposure to prescription opioids
Ø Incident ADF users may not be representative of the overall ADF user population. 
• In a prevalent new-user design: 
Ø Patients can be prescribed similar treatments (or potential comparators) before starting the new 
treatment.
Ø Likely better represents the intended ADF patient population. 
Background
To evaluate the appropriateness of traditional new-user vs. prevalent new-user design for estimating post-
market effectiveness of ADFs and examine patterns of ADF initiation. 
Objective
Data Source & Inclusion
• Pharmaceutical claims data 
• 2009-2018
• Large private insurer in North Carolina
Measures
• Traditional new-user
• Patients with no prescription opioid claims in a 6-month washout period prior to ADF 
initiation. 
• Prevalent new-user 
• Patients with non-ADF opioid claims during the 6 months before ADF initiation, so long as 
they also had a 6-month washout period of no opioid claims prior to first non-ADF opioid 
claim
Analysis
• We compared sample sizes by study design and described ADF utilization patterns.
Methods
Results
• Three-quarters of patients initiating ADFs had prior prescription opioid use and would be excluded in a 
traditional new-user study design. 
• A prevalent new-user design would increase sample size and better capture clinically meaningful patients. 
• These findings may apply to studies of other medications where prior exposure is a labeled prerequisite, 
such as higher dose ER opioids and second-line therapies. 
• Future work will explore prevalent new user designs and consider nuances in ADF initiation such as 
immediate versus delayed switching by incorporating time-matching to address opioid tolerance. 
Conclusions
This study was supported by funding from the US Food and Drug Administration (FDA) under Broad Agency Announcement No. 17–
00123 (Award No. HHSF223201810183C).
